As one of the most important post-translational modifications, ubiquitination plays versatile roles in cancer-related pathways, and is involved in protein metabolism, cell-cycle progression, apoptosis, and transcription. Counteracting the activities of the E3 ligases, the deubiquitylating enzymes have been suggested as another important mechanism to modulate the ubiquitination process, and are implicated in cancer as well. In this article, we review the emerging roles of USP28 in cancer pathways as revealed by recent studies. We discuss the major mechanisms by which USP28 is involved in the cancer-related pathways, whereby USP28 regulates physiological homeostasis of ubiquitination process, DNA-damage response, and cell cycle during genotoxic stress. We further review the studies where USP28 was targeted for treating multiples cancers including non-small cell lung cancer, breast cancer, intestinal cancers, gliomas, and bladder cancer. As a result, the clinical significance of targeting USP28 for cancer therapy merits further exploration and demonstration.
[1]Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
[2]Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
[3]Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
[4]Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
[5]First Hosp Nanjing, Dept Oncol, Nanjing 210000, Jiangsu, Peoples R China.
[6]Shanghai Univ Tradit Chinese Med, Canc Inst, Longhua Hosp, Shanghai 200032, Peoples R China.
(8.0+极速模式)